Browse the corpus

Duloxetine is a medication used to manage major depressive disorder (MDD), generalized anxiety disorder (GAD), fibromyalgia, diabetic peripheral neuropathy, and chronic musculoskeletal pain. Off-label uses for duloxetine include chemotherapy-induced peripheral neuropathy and stress urinary incontinence. It is in the Serotonin and norepinephrine reuptake inhibitors (SNRIs) class of medications. This activity describes the indications, mechanism of action, and contraindications for duloxetine as a valuable agent in treating multiple health conditions. This activity will highlight the mechanism of action, adverse event profile, and other key factors (e.g., off-label uses, dosing, pharmacodynamics, pharmacokinetics, monitoring, relevant drug-drug interactions) pertinent for members of the interprofessional team in the treatment of patients with major depressive disorder (MDD), generalized anxiety disorder (GAD), fibromyalgia, diabetic peripheral neuropathy, chronic musculoskeletal pain, and related conditions. Objectives: Identify the indications for the use of duloxetine. Describe the most common potential adverse events associated with duloxetine therapy. Explain the importance of monitoring for patients on duloxetine therapy and summarize key patient counseling points. Explain how the successful initiation and maintenance of effective therapy with duloxetine requires a well-coordinated interprofessional team approach. Access free multiple choice questions on this topic.

Fatal outcomes have occurred with overdoses at as low as 1000 mg. Signs and symptoms of overdose include serotonin syndrome, seizures, coma, somnolence, syncope, tachycardia, autonomic instability, diarrhea, and vomiting. Signs of serotonin syndrome include agitation, restlessness, disorientation, diaphoresis, hyperthermia, tachycardia, nausea, vomiting, tremor, muscle rigidity, hyperreflexia, myoclonus, dilated pupils, dry mucous membranes, and increased bowel sounds. Clonus and hyperreflexia are particularly common in serotonin syndrome. There is no antidote to duloxetine overdose. If the patient is presenting with serotonin syndrome, cyproheptadine and cooling measures may be considered. Patients with abnormal vital signs need monitoring, and severe cases may warrant ICU-level of care.[9][10]

Antidepressants including duloxetine may increase the risk of suicidal thinking and behavior in children, adolescents, and young adults who have a major depressive disorder and other psychiatric disorders. Close observation and routine follow-up by the healthcare team is essential in ensuring medication compliance and patient safety. When a patient is started on duloxetine therapy, all the interprofessional team members, including clinicians, mid-level practitioners, specialists, nurses, social workers, and pharmacists, should be involved in patient care. The pharmacist should perform a thorough medication reconciliation to preclude any drug interactions and verify that dosing is appropriate. A psychiatric health specialist nurse will assist with patient counseling regarding administration and monitor the patient on follow-up visits. If there are any warning symptoms or concerns, the pharmacist and nurse should inform the prescriber promptly. Any social workers or other mental health counselors also need to be included in the sharing of information. This type of interprofessional team approach can ensure optimal patient outcomes with minimal adverse events.